Excellent time than psoriatic arthritis monoclonal antibody Bimekizumab obtained positive 2 results December 21, 2017 Source: Sina Pharmaceutical On December 20th, the Belgian pharmaceutical company Euphoria said that bimekizumab's clinical phase 2b trial, BE ACTIVE, for psoriatic arthritis (PsA) treatment reached the primary end point of the study, achieving a statistically significant dose response. main target. The study also showed that, compared with placebo, bimekizumab had a strong effect on PsA patients' symptoms and PASI 90 lesion clearance after 12 weeks of treatment. Dr. Christopher T. Ritchlin of the University of Rochester Medical Center said: "The results of the bimekizumab clinical study are impressive, especially since the study included two rigorous and meaningful efficacy measures, ACR50 and PASI90. Even at 12 weeks of treatment, The results also show strong joint and skin relief, which is a great possibility for significant improvement in the two main affected symptoms of PsA patients. Comprehensive and specific inhibition of the inflammatory response is achieved The key to convincing results. Preclinical studies have shown that dual blocking of IL-17a and IL-17F inhibits joint and skin inflammation more than blocking IL-17a alone. Bimekizumab has the potential to be an important treatment option for patients with PsA. Many of them are unresponsive or intolerant of current treatment." Emmanuel Caeymaex, Senior Vice President and Head of Immunology at UBS, said: "The BE ACTIVE study confirms the conceptual validation of previous PsA patients and provides the efficacy of bimekizumab for Phase Ib clinical trials of PsA. Safety data. The Phase 3 clinical trial plan will be rapidly advanced. According to the results of Phase 2b trials in all three disease states, bimekizumab has the potential to bring significant and differentiated clinical value to patients." The BE ACTIVE study data was based on the positive clinical outcome of Bimekizumab in the treatment of psoriasis and ankylosing spondylitis (AS). In this study of patients with severe PsA, bimekizumab achieved complete clearance of lesions (PASI100) in 60% of patients at 12 weeks of treatment with dual inhibition of IL-17A and IL-17F. The Phase 2b study of AS patients also reached the primary end point of treatment (ASAS40), with more than 47% of patients receiving bimekizumab achieving at least a 40% improvement in AS symptoms, compared with only 13% of patients in the placebo group. This indicator. Both PsA and AS are manifestations of spinal arthritis and belong to the field of rheumatology, usually involving axial bones and peripheral joints, which are distinctly different from rheumatoid arthritis. The BE ACTIVE study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of bimekizumab compared to placebo in adult patients with psoriatic arthritis. The primary efficacy variable evaluated in this Phase 2b study was the percentage of patients with PsA who achieved at least 50% improvement in disease after treatment at Week 12, as measured by the American College of Rheumatology (ACR 50). The study also had several secondary study endpoints, including the number of patients with at least 90% of psoriatic lesion clearance (PASI90) at 12 weeks. Bimekizumab achieved more major and minor clinical remission thresholds than placebo at multiple doses. In addition, Bimekizumab was well tolerated and no new safety risks were observed. The common cold (pharyngitis) is the most common adverse event compared to the placebo group. The BE ACTIVE study will continue for 36 weeks to assess the efficacy and safety of Bimcikizumab in a dose-blind manner. Bimekizumab is a human IgG1 monoclonal antibody that efficiently and selectively inhibits two key cytokines, IL-17A and IL-17F, in the inflammatory process. IL-17A and IL-17F have overlapping pro-inflammatory functions and synergistically interact with other inflammatory mediators, respectively, driving chronic inflammation and damage across multiple tissues. (Sina Pharmaceutical Compilation / David) Article reference source: https:// -demonstrates-impressive-joint-and-skin-responses-for-psoriatic-arthritis-patients-nbsp YT-H706 YT-H706 Shenzhen Sunshine Technology Co.,Ltd , https://www.yatwinsz.com